These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9561067)

  • 1. Pharmacokinetic and hemodynamic safety of two superparamagnetic agents, Endorem and Sinerem, in cirrhotic rats.
    Bonnemain B
    Acad Radiol; 1998 Apr; 5 Suppl 1():S151-3; discussion S156. PubMed ID: 9561067
    [No Abstract]   [Full Text] [Related]  

  • 2. Superparamagnetic iron oxide nanoparticles: nodal metastases and beyond.
    Anzai Y
    Top Magn Reson Imaging; 2004 Apr; 15(2):103-11. PubMed ID: 15269613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependency and rate of decay of efficacy of Resovist on MR images in a rat cirrhotic liver model.
    Kato N; Takahashi M; Tsuji T; Ihara S; Brautigam M; Miyazawa T
    Invest Radiol; 1999 Sep; 34(9):551-7. PubMed ID: 10485069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental investigation of the delivery pathway of ultrasmall superparamagnetic iron oxide to lymph nodes.
    Frija G; Clément O; Le Guen O; Cuénod CA; Siauve N; Benderbous S
    Acad Radiol; 1996 Aug; 3 Suppl 2():S299-300. PubMed ID: 8796586
    [No Abstract]   [Full Text] [Related]  

  • 5. MR lymphography: evidence of extravasation of superparamagnetic nanoparticles into the lymph.
    Clement O; Rety F; Cuenod CA; Siauve N; Carnot F; Bordat C; Siche M; Frija G
    Acad Radiol; 1998 Apr; 5 Suppl 1():S170-2; discussion S183-4. PubMed ID: 9561073
    [No Abstract]   [Full Text] [Related]  

  • 6. Susceptibility-based MRI contrast of the CSF by intravascular superparamagnetic nanoparticles.
    Yu O; Namer IJ; Steibel J; Eclancher B; Poulet P; Chambron J
    MAGMA; 1995; 3(3-4):169-72. PubMed ID: 8749736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide.
    Hamm B; Staks T; Taupitz M; Maibauer R; Speidel A; Huppertz A; Frenzel T; Lawaczeck R; Wolf KJ; Lange L
    J Magn Reson Imaging; 1994; 4(5):659-68. PubMed ID: 7981510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Overview of MRI contrast media. The case of endorem].
    Duroux M
    Radiologe; 1995 Nov; 35(11 Suppl 2):S247-8. PubMed ID: 8588029
    [No Abstract]   [Full Text] [Related]  

  • 9. [Use of ultrasmall ferric oxide (Sinerem) particles as a magnetic resonance contrast substance for imaging lymph nodal metastases in cancer of the head and neck].
    Sviridov NK; Napolov IuK; Bolotova EN; Iakobs LV
    Vestn Rentgenol Radiol; 2004; (3):63-4. PubMed ID: 15587888
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro.
    Müller K; Skepper JN; Posfai M; Trivedi R; Howarth S; Corot C; Lancelot E; Thompson PW; Brown AP; Gillard JH
    Biomaterials; 2007 Mar; 28(9):1629-42. PubMed ID: 17178155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of contrast enhancement with iron oxides.
    Frija G; Clément O; de Kerviler E
    Invest Radiol; 1994 Jun; 29 Suppl 2():S75-7. PubMed ID: 7928276
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism.
    Pouliquen D; Le Jeune JJ; Perdrisot R; Ermias A; Jallet P
    Magn Reson Imaging; 1991; 9(3):275-83. PubMed ID: 1881245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in hepatic uptake and distribution of organ-specific superparamagnetic MRI contrast media: clinical findings and classification according to pathogenesis.
    Macarini L; Marini S; Murrone M; Ettorre GC
    Radiol Med; 2004; 108(1-2):92-106. PubMed ID: 15269693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The endorem tolerance profile].
    Laniado M; Chachuat A
    Radiologe; 1995 Nov; 35(11 Suppl 2):S266-70. PubMed ID: 8588033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients.
    Chachuat A; Bonnemain B
    Radiologe; 1995 Nov; 35(11 Suppl 2):S274-6. PubMed ID: 8588035
    [No Abstract]   [Full Text] [Related]  

  • 16. Transferrin receptor expression in iron oxide-labeled mesenchymal stem cells.
    Pawelczyk E; Frank JA
    Radiology; 2008 Jun; 247(3):913; author reply 914-5. PubMed ID: 18487546
    [No Abstract]   [Full Text] [Related]  

  • 17. Dynamic signal intensity changes in liver with superparamagnetic MR contrast agents.
    Reimer P; Kwong KK; Weisskoff R; Cohen MS; Brady TJ; Weissleder R
    J Magn Reson Imaging; 1992; 2(2):177-81. PubMed ID: 1562768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the time window for Resovist-enhanced T2-weighted MRI of the liver.
    Reimer P; Müller M; Marx C; Balzer T
    Acad Radiol; 2002 Aug; 9 Suppl 2():S336-8. PubMed ID: 12188267
    [No Abstract]   [Full Text] [Related]  

  • 19. Ferrite particles (AMI25). Influence of cirrhosis and chemotherapy on magnetic resonance imaging of metastasis.
    Clement O; Schouman-Claeys E; Frija G
    Invest Radiol; 1990 Sep; 25 Suppl 1():S61-2. PubMed ID: 2126536
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat.
    Majumdar S; Zoghbi SS; Gore JC
    Invest Radiol; 1990 Jul; 25(7):771-7. PubMed ID: 2391194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.